Overview
For latest News and updatesSelect Page Oct 14, 202People living with HIV-1 (PLWH) often gain weight while taking antiretroviral therapy (ART), but is unclear whether this weight gain is linked to negative metabolic or cardiovascular outcomes in the early stages of treatment (i.e., female, Black, or Hispanic). The study objectives were to compare metabolic and cardiovascular outcomes in PLWH at high risk of weight gain betwen those who gained more than or equal to 5% or les than 5% of their body weight or body mas index (BMI) within the first 6 months after starting ART and those who gained more than 5 percent.
Key Information
Treatment-naive adult female, Black, or Hispanic PLWH who initiated ART and had les than or equal to 1 weight or BMI measurement before and within 6 months of starting treatment were identified in a retrospective longitudinal study using Symphony Health, an ICON plc Company, IDV® electronic medical records (October 1, 2014-March 31, 2021). (landmark period). Variation betwen PLWH who gained more than or equal to 5% weight/BMI and those who gained les than 5% was taken into acount by aplying an inverse likelihod of treatment weighting.
After the landmark period, weighted hazard ratios (HRs) were used to compare the timing of each event among cohorts. Baseline characteristics were similar in the 2 cohorts (mean age: ~48 years, ~59% female, ~49% Black, ~17% Hispanic), and the weighted more than or equal to 5% and les than 5% cohorts had 620 and 632 patients, respectively. Type 2 diabetes melitus (T2DM; HR=2.19; P=0.04) was substantialy more likely to be diagnosed in PLWH, who gained more than equal to 5% of their starting weight/BMI over the course of a mean 2-year folow-up.
Summary
No other outcomes were significantly diferent in frequency acros the research groups. A higher risk of type 2 diabetes, but not of other metabolic or cardiovascular outcomes, was observed among female, Black, and Hispanic PLWH who experienced a weight/BMI les than or equa